Orphazyme A/S (NASDAQ:ORPH) trading with a subtraction of -$0.54 to $4.37 on Thursday, a downside of -11.00 percent. An average of 4,802,382 shares of common stock have been traded in the last five days. There was a gain of $0.49 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 1,715,711 shares traded, while the 50-day average volume stands at 4,434,028.
ORPH stock has increased by 7.44% in the last month. The company shares reached their 1-month lowest point of $3.78 on 10/08/21. With the stock rallying to its 52-week high on 06/10/21, shares of the company touched a low of $3.78 and a high of $77.77 in 52 weeks. It has reached a new high 9 times so far this year and lost -54.24% or -$6.33 in price. In spite of this, the price is down -94.38% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Orphazyme A/S (ORPH) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.77 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 89.71, the price-to-book (PB) ratio at 6.64.
The quick ratio of Orphazyme A/S for the recent quarter was 1.80, and the current ratio was 1.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.14 and a total debt to equity ratio of 0.35 for the recent quarter. Its gross profit as reported stood at -$93.23 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Orphazyme A/S’s return on assets was -160.50%, compared to -82.4% over the last five years. Meanwhile, the return on equity (ROE) for the past 12 months has been -251.20% and the 5-year average holds at -110.6%. For the broader industry, ROE averaged -68.79 over the past year.
From a technical analysis perspective, let’s take a brief look at Orphazyme A/S (ORPH) price momentum. RSI 9-day as of the close on 13 October was 53.67%, suggesting the stock is Neutral, with historical volatility in this time frame at 130.23%.
As of today, ORPH’s price is $4.21 +12.53% or $0.49 from its 5-day moving average. ORPH is currently trading -4.35% lower than its 20-day SMA and -22.10% lower than its 100-day SMA. However, the stock’s current price level is -0.45% below the SMA50 and -60.78% below the SMA200.
The stochastic %K and %D were 42.15% and 31.33%, respectively, and the average true range (ATR) was 0.41. With the 14-day stochastic at 36.26% and the average true range at 0.39, the RSI (14) stands at 50.07%. The stock has reached 0.34 on the 9-day MACD Oscillator while the 14-day reading was at 0.30.
Guggenheim downgraded Orphazyme A/S (NASDAQ: ORPH) to a a Sell rating in its most recent analyst report. Previously, the stock was rated as a a Buy.The consensus rating for Orphazyme A/S (ORPH) among analysts is Underweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell ORPH, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is ORPH’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $2.06, with a median target of $1.53. Taking a look at these predictions, the average price target given by analysts for Orphazyme A/S (ORPH) stock is $1.53.